Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cellular Signalling

• Publication date

  2015-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.cellsig.2014.12.003PMID 25499621
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The microRNA miR-34a Inhibits Non-Small Cell Lung Cancer (NSCLC) Growth and the CD44hi Stem-Like NSCLC Cells

  2014cited by this paper
• Dysregulation of MicroRNA-34a Expression in Colorectal Cancer Inhibits the Phosphorylation of FAK Via VEGF

  2014cited by this paper
• MicroRNA-92a Negatively Regulates Toll-like Receptor (TLR)-triggered Inflammatory Response in Macrophages by Targeting MKK4 Kinase*

  2013cited by this paper
• Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation.

  2013cited by this paper
• Increased expression of programmed death (PD)‐1 and its ligand PD‐L1 correlates with impaired cell‐mediated immunity in high‐risk human papillomavirus‐related cervical intraepithelial neoplasia

  2013cited by this paper
• PTEN/PI3K/mTOR/B7-H1 signaling pathway regulates cell progression and immuno-resistance in pancreatic cancer.

  2013cited by this paper
• A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma

  2013cited by this paper
• miR-34 – a microRNA replacement therapy is headed to the clinic

  2012cited by this paper
• The role of MicroRNAs miR-200b and miR-200c in TLR4 signaling and NF-κB activation

  2012cited by this paper
• MicroRNA-34a Modulates c-Myc Transcriptional Complexes to Suppress Malignancy in Human Prostate Cancer Cells

  2012cited by this paper
• MicroRNA-107, an oncogene microRNA that regulates tumour invasion and metastasis by targeting DICER1 in gastric cancer

  2011cited by this paper
• The Role of MicroRNAs in Regulatory T Cells and in the Immune Response

  2011cited by this paper
• Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

  2010cited by this paper
• Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34.

  2010cited by this paper
• microRNA-34a is tumor suppressive in brain tumors and glioma stem cells

  2010cited by this paper
• Regulation of mRNA translation and stability by microRNAs.

  2010cited by this paper
• siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells.

  2010cited by this paper
• MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN-γ-Induced B7-H1 Expression in Cholangiocytes12

  2009cited by this paper
• PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

  2009cited by this paper
• MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors.

  2009cited by this paper
• miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities

  2009cited by this paper
• A 3′-Untranslated Region (3′UTR) Induces Organ Adhesion by Regulating miR-199a* Functions

  2009cited by this paper
• Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis.

  2008cited by this paper
• [Expression and significance of B7-H1 and its receptor PD-1 in human gastric carcinoma].

  2008cited by this paper
• MHC class I assembly: out and about.

  2008cited by this paper
• Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

  2007cited by this paper
• The Net Effect of Costimulatory Blockers Is Dependent on the Subset and Activation Status of the Autoreactive T Cells1

  2007cited by this paper
• Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

  2007cited by this paper
• The evolution of gene regulation by transcription factors and microRNAs

  2007cited by this paper
• Mechanisms of MHC class I‐restricted antigen processing and cross‐presentation

  2005cited by this paper
• MicroRNAs as oncogenes and tumor suppressors.

  2005cited by this paper
• c-Myc-regulated microRNAs modulate E2F1 expression

  2005cited by this paper
• Intensified Cloning Efforts Have Revealed Numer

  2004cited by this paper
• Negative feedback of T cell activation through inhibitory adapters and costimulatory receptors

  2003cited by this paper
• Prediction of mammalian microRNA targets.

  2003cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex

  2001cited by this paper

• An immune-related signature based on molecular subtypes for predicting the prognosis and immunotherapy efficacy of hepatocellular carcinoma

  2025cites this paper
• Activation of the circAGFG1/miR-195-5p/PD-L1 axis induces lung injury in sepsis

  2025cites this paper
• MiR-340-5p regulates PD-L1 and predicts pembrolizumab response in extranodal NK/T-cell lymphoma

  2025cites this paper
• MicroRNA-mediated regulation of natural killer cells development, effector functions, and antitumor responses

  2025cites this paper
• Harnessing p53 for targeted cancer therapy: new advances and future directions

  2025cites this paper
• Effect of conditioned medium from miRNA-34a transfected gastric cancer-associated fibroblast on peripheral blood mononuclear cells

  2025cites this paper
• MicroRNA-34a enhances immune response and suppresses PI3K/AKT signaling through targeting PD-L1 in triple-negative breast cancer

  2025cites this paper
• Tumor-derived small extracellular vesicles loaded with functionally active miR-34a mimic can modify the anti-tumor response in 4T1 breast cancer animal model

  2025cites this paper
• Co-regulation of miRNA and lncRNA on immunosuppression gene: unveiling the regulatory networks in cancer.

  2025cites this paper
• Utilizing miR-34a-Loaded HER2-Targeting Exosomes to Improve Breast Cancer Treatment: Insights From an Animal Model

  2025influential citation
• MicroRNAs in the abscopal effect: bridging radiotherapy and systemic anti-tumor immunity for enhanced cancer therapy

  2025cites this paper
• MircoRNAs predict and modulate responses to chemotherapy in leukemic patients

  2025influential citation
• Redesigning miR-34a: structural and chemical advances in the therapeutic development of an miRNA anti-cancer agent

  2025cites this paper
• Mechanism of Action of circRNA/miRNA Network in DLBCL

  2025cites this paper
• Role of MicroRNAs in Acute Myeloid Leukemia

  2025cites this paper
• Non-coding RNA biomarkers in basal-like breast cancer.

  2025cites this paper
• Effects of sesamin on the chemosensitivity, invasiveness and immune evasion mechanism of human lung adenocarcinoma

  2025cites this paper
• MicroRNA-mediated metabolic regulation of immune cells in cancer: an updated review

  2024cites this paper
• Lower expressions of MIR34A and MIR31 in colo-rectal cancer are associated with an enriched immune microenvironment.

  2024cites this paper
• Reactive oxygen species/glutathione dual sensitive nanoparticles with encapsulation of miR155 and curcumin for synergized cancer immunotherapy

  2024cites this paper
• The NOTCH1 and miR-34a signaling network is affected by TP53 alterations in CLL

  2024cites this paper
• Bone marrow microRNA-34a is a good indicator for response to treatment in acute myeloid leukemia

  2024cites this paper
• PD-L1 and PD-1 in Immune Regulation and Their Implications in Blood Cancers

  2024cites this paper
• Myeloid Mir34a suppresses colitis-associated colon cancer: characterization of mediators by single-cell RNA sequencing

  2024cites this paper
• Integrating p53-associated genes and infiltrating immune cell characterization as a prognostic biomarker in multiple myeloma

  2024cites this paper
• Immunotherapeutic IL-6R and targeting the MCT-1/IL-6/CXCL7/PD-L1 circuit prevent relapse and metastasis of triple-negative breast cancer

  2024cites this paper
• The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment.

  2024cites this paper
• Lnc-CCNH-8 promotes immune escape by up-regulating PD-L1 in hepatocellular carcinoma

  2024cites this paper
• Non-Coding RNA-Targeted Therapy: A State-of-the-Art Review

  2024cites this paper
• A novel therapeutic strategy: the significance of exosomal miRNAs in acute myeloid leukemia

  2024cites this paper
• The IRE1α Endonuclease Plays a Dual Role in Regulating the XBP1/miRNA-34a Axis and PD-1 Expression within Natural Killer Cells in Hodgkin Lymphoma

  2024cites this paper
• Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors

  2023cites this paper
• MicroRNA-34 Family in Cancers: Role, Mechanism, and Therapeutic Potential

  2023cites this paper
• MicroRNA-Mediated Regulation of Histone-Modifying Enzymes in Cancer: Mechanisms and Therapeutic Implications

  2023cites this paper
• A first-in-class fully modified version of miR-34a with outstanding stability, activity, and anti-tumor efficacy

  2023cites this paper
• Helicobacter pylori CagA promotes immune evasion of gastric cancer by upregulating PD-L1 level in exosomes

  2023cites this paper
• The Role of lncRNA-miR-26a-mRNA Network in Cancer Progression and Treatment

  2023cites this paper
• Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors

  2023cites this paper
• Osteoclast microRNA Profiling in Rheumatoid Arthritis to Capture the Erosive Factor

  2023cites this paper
• High PD-L1 expression is associated with unfavorable clinical features in myelodysplastic neoplasms

  2023cites this paper
• Microproteins: Overlooked regulators of physiology and disease

  2023cites this paper
• Cosmosiin Induces Apoptosis in Colorectal Cancer by Inhibiting PD-L1 Expression and Inducing ROS

  2023cites this paper
• The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells

  2023cites this paper
• Cancer‐derived non‐coding RNAs endow tumor microenvironment with immunosuppressive properties

  2023cites this paper
• An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response

  2023cites this paper
• Exosomal microRNAs in cancer: Potential biomarkers and immunotherapeutic targets for immune checkpoint molecules

  2023cites this paper
• The IRE1α-endonuclease regulates PD-1 expression through a novel XBP1/miRNA-34a axis within Natural Killer cells

  2023cites this paper
• Research progress of aging-related microRNAs.

  2023cites this paper
• circFANCA accelerates the malignant process of OSCC by modulating miR-34a/PA28γ signaling.

  2023cites this paper
• Natural killer cell epigenetic reprogramming in tumors and potential for cancer immunotherapy.

  2023cites this paper
• Liujunzi decoction exerts potent antitumor activity in oesophageal squamous cell carcinoma by inhibiting miR-34a/STAT3/IL-6R feedback loop, and modifies antitumor immunity.

  2023cites this paper
• Tumor suppressive functions of hsa-miR-34a on cell cycle, migration and protective autophagy in bladder cancer

  2023cites this paper
• Molecular mechanism of miRNA regulating PD-L1 expression

  2023cites this paper
• Unpacking the Complexity of Epithelial Plasticity: From Master Regulator Transcription Factors to Non-Coding RNAs

  2023cites this paper
• MicroRNA of extracellular vesicles as biomarkers and regulators of pathological and physiological processes

  2023cites this paper
• Comparing the Variants of Iron Oxide Nanoparticle-Mediated Delivery of miRNA34a for Efficiency in Silencing of PD-L1 Genes in Cancer Cells

  2023cites this paper
• EBV and Lymphomagenesis

  2023cites this paper
• The Interaction of Programmed Cell Death Protein and Its Ligands with Non-Coding RNAs in Neoplasms: Emerging Anticancer Immunotherapeutics

  2023cites this paper
• Evaluation of miR-200c-3p and miR-421-5p levels during immune responses in the admitted and recovered COVID-19 subjects

  2022cites this paper
• AM22, a novel synthetic microRNA, inhibits the proliferation of colorectal cancer cells by targeting core binding factor subunit β (CBFB)

  2022cites this paper
• The Role of 8-oxoG Repair Systems in Tumorigenesis and Cancer Therapy

  2022cites this paper
• PD-L1 Targeted Immunoliposomes with PD-L1 siRNA and HDAC Inhibitor for Anti-Lung Cancer Immunotherapy

  2022cites this paper
• MicroRNAs and their role in immunogenetic-dysregulation

  2022cites this paper
• The Roles of MiRNAs (MicroRNAs) in Melanoma Immunotherapy

  2022cites this paper
• p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target

  2022cites this paper
• MicroRNAs in T Cell-Immunotherapy

  2022cites this paper
• Current insight into the regulation of PD-L1 in cancer

  2022cites this paper
• Autophagy blockade potentiates cancer‐associated immunosuppression through programmed death ligand‐1 upregulation in bladder cancer

  2022cites this paper
• MicroRNAs and Long Non-coding RNAs as Novel Targets in Anti-cancer Drug Development.

  2022cites this paper
• The Features of Immune Checkpoint Gene Regulation by microRNA in Cancer

  2022cites this paper
• Generation, secretion and degradation of cancer immunotherapy target PD-L1

  2022cites this paper
• MicroRNA-29a attenuates CD8 T cell exhaustion and induces memory-like CD8 T cells during chronic infection

  2022cites this paper
• EGFR signaling pathway as therapeutic target in human cancers.

  2022cites this paper
• Transcriptional and post-transcriptional regulation of checkpoint genes on the tumour side of the immunological synapse

  2022cites this paper
• Noncoding RNAs as novel immunotherapeutic tools against cancer.

  2022cites this paper
• Long non-coding RNA Opa interacting protein 5-antisense RNA 1 binds to micorRNA-34a to upregulate oncogenic PD-L1 in non-small cell lung cancer

  2022cites this paper
• Bioengineered miR-34a modulates mitochondrial inner membrane protein 17 like 2 (MPV17L2) expression toward the control of cancer cell mitochondrial functions

  2022cites this paper
• PD-L1 and JAK2 mRNA level in essential thrombocythaemia depends on the driver mutational status and the bone marrow fibrosis grade

  2022cites this paper
• Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

  2022cites this paper
• Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53

  2022cites this paper
• MIO: microRNA target analysis system for immuno-oncology

  2022cites this paper
• Nanotechnology in Immunotherapy for Type 1 Diabetes: Promising Innovations and Future Advances

  2022cites this paper
• The therapeutic effect of exosomes from mesenchymal stem cells on colorectal cancer: Toward cell-free therapy.

  2022cites this paper
• Tumor immune checkpoints and their associated inhibitors

  2022cites this paper
• Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies

  2022cites this paper
• The emerging role of miRNA in the perturbation of tumor immune microenvironment in chemoresistance: Therapeutic implications.

  2021cites this paper
• Concomitant inhibition of B7-H3 and PD-L1 expression by a novel and synthetic microRNA delivers potent antitumor activities in colorectal tumor models

  2021cites this paper
• miRNAs as novel immunoregulators in cancer.

  2021cites this paper
• Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

  2021cites this paper
• miRNA Expression Characterizes Histological Subtypes and Metastasis in Penile Squamous Cell Carcinoma

  2021cites this paper
• Oleuropin controls miR-194/XIST/PD-L1 loop in triple negative breast cancer: New role of nutri-epigenetics in immune-oncology.

  2021cites this paper
• MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic

  2021cites this paper
• B-cell acute lymphoblastic leukemia-related microRNAs: uncovering their diverse and special roles.

  2021cites this paper
• Delivery of miR-424-5p via Extracellular Vesicles Promotes the Apoptosis of MDA-MB-231 TNBC Cells in the Tumor Microenvironment

  2021cites this paper
• Regulation of PD-L1 expression in the tumor microenvironment

  2021cites this paper
• MicroRNAs Associated With a Good Prognosis of Acute Myeloid Leukemia and Their Effect on Macrophage Polarization

  2021influential citation
• miR-34a induces immunosuppression in colorectal carcinoma through modulating a SIRT1/NF-κB/B7-H3/TNF-α axis

  2021cites this paper
• The comprehensive landscape of miR-34a in cancer research

  2021cites this paper
• The anti-tumor effects of CT-26 derived exosomes enriched by MicroRNA-34a on murine model of colorectal cancer.

  2021cites this paper
• PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?

  2021cites this paper